Stryker hip implant lawsuits: how the LFIT V40 and Rejuvenate/ABG II litigation actually resolved and what's still pending

The Stryker hip implant litigation represents one of the most substantial medical device mass torts resolved over the past decade, with two distinct federal Multidistrict Litigations addressing different product recalls. MDL 2441 (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation) in the U.S. District Court for the District of Minnesota before Senior Judge Donovan W. Frank addressed the July 2012 voluntary recall of Stryker's Rejuvenate and ABG II Modular Hip Systems. MDL 2768 (In re: Stryker LFIT Anatomic CoCr V40 Femoral Head Products Liability Litigation) in the U.S. District Court for the District of Massachusetts before Judge Indira Talwani addressed the September 2016 voluntary recall of the LFIT Anatomic CoCr V40 Femoral Head. The two MDLs operated in parallel — different products, different recall events, different procedural frameworks, but similar underlying allegations about metal-on-metal hip implant defects.

The substantive theory in both litigations centers on the same fundamental defect mechanism: metal-on-metal hip implants released cobalt and chromium metal ions into surrounding tissue and the patient's bloodstream, causing metallosis (metal poisoning), pseudotumors, bone loss (osteolysis), chronic pain, and the need for revision surgery to remove and replace the failed implant. The metal-on-metal design produces friction between cobalt-chromium femoral head components and corresponding stem or acetabular components, generating microscopic metal debris that accumulates in surrounding tissue. The biological response includes substantial inflammatory reaction, formation of fluid collections (pseudotumors), and progressive bone destruction. Affected patients typically experience pain at progressively higher levels, reduced mobility, and ultimately need for revision surgery to address the failing implant.

The substantial resolution of these litigations occurred through two major settlements: the November 3, 2014 global settlement for the Rejuvenate and ABG II products at approximately $1.4 billion, providing a minimum award of $300,000 to most eligible victims (one of the largest minimum settlements in failed hip replacement litigation history); and a confidential $75 million settlement program covering approximately 2,500 claims by 500 plaintiffs for the LFIT V40 products. Both settlement programs included substantial procedural framework for individual case evaluation, medical record review, and damage calculation. As of January 2026, MDL 2441 has approximately 16 pending cases remaining, while MDL 2768 has approximately 55-62 pending cases. Both MDLs continue accepting some new cases involving the LFIT V40 products, but the substantial settlement framework has substantially resolved the majority of cases. A separate emerging litigation involves the Tritanium Acetabular Shell — newer Stryker hip implant component with similar alleged manufacturing defects.

This is how the Stryker hip implant litigation actually worked through its two parallel MDL structures, the substantive theory of metal-on-metal hip implant failure, the procedural history of both recalls and settlements, the framework for current and prospective plaintiffs, and the strategic considerations for affected patients pursuing remaining claims.

What Stryker hip implants are and the alleged defect

Hip replacement surgery typically involves three components:

The femoral component. Replaces the upper part of the femur (thigh bone):

Stem inserted into femoral canal
Neck/taper component connecting to femoral head
Often modular with multiple connection points

The femoral head. Ball component that replaces the natural femoral head:

Articulates with the acetabular cup
Typically made of cobalt-chromium, ceramic, or other materials
Available in various sizes

The acetabular component. Cup replacing the hip socket:

Outer shell (often titanium or other metal)
Inner liner (polyethylene, ceramic, or metal)
Allows articulation with femoral head

The Stryker Rejuvenate Modular-Neck Hip Stem. Distinctive product features:

Modular design with multiple components
Cobalt-chromium modular neck component
Titanium femoral stem
Modular junction between neck and stem
Designed for hip replacement surgery

The Stryker ABG II Modular-Neck Hip Stem. Similar design:

Modular neck design
Cobalt-chromium components
Modular junction concerns

The Stryker LFIT Anatomic CoCr V40 Femoral Head. Component used in various Stryker hip systems:

Cobalt-chromium (CoCr) construction
V40 taper design
Used with Accolade, Accolade 2, Citation, Meridian, Rejuvenate, and other stem systems
Various sizes (36mm, 38mm, 40mm, 44mm primarily)

The alleged defect mechanism. Both product lines share similar defect theories:

Modular junction corrosion (Rejuvenate and ABG II). Where the modular neck meets the femoral stem:

Friction and corrosion at junction
Cobalt and chromium release from cobalt-chromium components
Mechanical loosening
Progressive failure

Trunnion failure (LFIT V40). Where the femoral head meets the femoral stem:

Taper junction failure
Fretting corrosion at taper interface
Cobalt-chromium ion release
Mechanical disconnection in severe cases

The biological response. Metal ion release produces:

Adverse Local Tissue Reaction (ALTR)
Pseudotumors (fluid-filled masses)
Aseptic Lymphocytic Vasculitis-Associated Lesion (ALVAL)
Substantial bone loss (osteolysis)
Soft tissue destruction
Possible systemic toxicity from elevated metal levels

Symptoms experienced by affected patients:

Persistent or worsening hip pain (typically several years post-implant)
Reduced range of motion
Audible clicking, squeaking, or grinding
Hip instability
Swelling around hip joint
Walking difficulty
Detection of elevated blood cobalt levels (>7 ppb concerning)

The alleged injuries

Plaintiffs in both MDLs alleged various injuries:

Metallosis (metal poisoning). Elevated cobalt and chromium levels:

Blood testing showing elevated metal ion levels
Tissue testing showing metal deposits
Systemic symptoms in severe cases
Cardiomyopathy in rare severe cases
Neurological symptoms in severe cases

Pseudotumors. Fluid-filled or solid masses developing around implant:

Imaging-detected (MRI, ultrasound)
May require surgical removal
Substantial soft tissue effects
Progressive growth in some cases

Aseptic Lymphocytic Vasculitis-Associated Lesion (ALVAL). Immune-mediated reaction:

Lymphocyte infiltration
Tissue destruction
Inflammatory response
Difficult to manage clinically

Bone loss (osteolysis). Progressive bone destruction:

Around the implant
Affecting surrounding bone structure
Compromising implant fixation
Complicating revision surgery
Sometimes requiring substantial bone grafting

Revision surgery requirement. Most affected patients required revision:

Failed primary implant removal
Replacement with new components
Substantial recovery period
Cost typically $50,000-$150,000+
Increased complication risk vs. primary surgery
Possible permanent disability from revision

Long-term complications:

Permanent loss of hip function
Need for additional revisions
Soft tissue destruction not fully recoverable
Bone loss not fully recoverable
Chronic pain management requirements
Permanent disability in some cases

Wrongful death (rare). Some severe metallosis cases:

Cardiomyopathy from systemic cobalt toxicity
Surgical complications
Other serious complications
Wrongful death framework applies

The procedural history of Stryker hip litigation

The litigation developed through two parallel tracks:

Rejuvenate and ABG II track (MDL 2441)

2008-2010. Stryker launches Rejuvenate Modular-Neck Hip System.

2009-2012. Increasing reports of modular junction failures.

July 6, 2012. Stryker voluntarily recalls Rejuvenate and ABG II Modular Hip Systems. Initial reports of corrosion and fretting at modular neck junctions.

Late 2012-2013. Substantial lawsuit filings begin.

June 12, 2013. Judicial Panel on Multidistrict Litigation establishes MDL 2441 (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation) in District of Minnesota.

Judge Donovan W. Frank assigned to oversee.

Bergen County, New Jersey state court litigation. Substantial parallel state court action.

November 3, 2014. Stryker announces global settlement program for eligible U.S. patients:

Estimated $1.4 billion total settlement value
Eligibility: Revision surgery before November 3, 2014 for reasons related to recall
Minimum award $300,000 to most victims (largest minimum in hip replacement litigation history)
Substantial procedural framework
Future compensation potential for previously settled cases
Individual case evaluation framework

2015-2018. Substantial settlement processing and individual case resolution.

2019-Present. Limited new cases. MDL technically remains open.

Current status (January 2026). Approximately 16 cases pending in MDL 2441.

LFIT V40 track (MDL 2768)

2002-2016. Stryker manufactures and markets LFIT V40 Femoral Heads in various sizes. Used in numerous hip implant systems.

September 2016. Stryker issues voluntary recall of LFIT Anatomic CoCr V40 Femoral Heads. Reports of taper junction failures.

Late 2016-2017. Substantial lawsuit filings begin.

April 5, 2017. Judicial Panel on Multidistrict Litigation establishes MDL 2768 (In re: Stryker LFIT V40 Femoral Head Products Liability Litigation) in District of Massachusetts.

Judge Indira Talwani assigned to oversee.

New Jersey Multicounty Litigation (MCL 624). Substantial parallel state court action in Bergen County.

Late 2018-2019. Active discovery and motion practice.

2020-2021. Substantial settlement negotiations.

November-December 2021. Master Settlement Agreement reached:

Confidential settlement program
$75 million total settlement
500 plaintiffs / ~2,500 claims
Stay of discovery entered to facilitate settlement
"Aiding Private Settlement" order December 2021
Substantial individual case evaluation framework
Compensation based on level of harm and components removed
Eligible: Recalled and unrecalled cobalt chromium V40 heads
Compatible stems: Accolade TMZF, Accolade 2, Citation, Meridian, Rejuvenate

Current status (January 2026). Approximately 55-62 cases pending in MDL 2768.

Tritanium Acetabular Shell emerging litigation

February 2024-Present. Ongoing litigation against Stryker:

Tritanium Acetabular Shell allegations
Manufacturing defects claimed
Various health issues and injuries alleged
Pre-MDL phase
Substantial growth potential

The procedural framework of the settlements

The Stryker settlements established procedural standards for hip implant litigation:

Rejuvenate/ABG II settlement framework

Base award. $300,000 minimum to most eligible plaintiffs:

Substantial baseline compensation
Available without litigation
Streamlined evaluation process

Enhancements available. Additional compensation for:

Severe metallosis
Wrongful death
Multiple revision surgeries
Substantial complications
Permanent disability

Eligibility requirements:

Stryker Rejuvenate or ABG II Modular Hip System recipient
Revision surgery before November 3, 2014
Reasons related to the recall (corrosion, fretting, modular junction failure)
Substantial medical documentation

Procedural framework:

Application through plaintiffs' counsel
Medical record review
Independent medical evaluation
Damage calculation
Settlement offer
Plaintiff acceptance or litigation election

Reductions limited. Per settlement terms:

Few reductions from base award
Strong settlement framework for plaintiffs
Quick payment after acceptance

Future compensation. Substantial provision:

Subsequent complications eligible
Future revision surgeries covered
Long-term compensation potential

LFIT V40 settlement framework

Master Settlement Agreement. Confidential structure:

Individual case valuation
Based on level of harm
Components removed during revision
Compatible stem systems considered
Substantial individual variation in awards

Eligibility:

Recalled or unrecalled LFIT V40 femoral heads
Compatible stem systems
Documented injuries
Revision surgery typically required

Compensation factors:

Severity of metallosis
Need for revision surgery
Complications
Permanent injury
Loss of function
Lost wages
Pain and suffering

Settlement amounts vary substantially. Without public disclosure:

Range from modest awards to substantial amounts
Confidentiality terms
Individual case evaluation

How to evaluate eligibility for remaining cases

The framework for current and prospective plaintiffs:

Documenting the Stryker product

Critical first step. Verify which Stryker product:

Surgical records (operative report)
Implant card (if patient received)
Hospital records identifying specific product and component
Lot numbers and serial numbers
Surgeon's office records

Components to identify:

Specific product line (Rejuvenate, ABG II, LFIT V40, other)
Component sizes
Specific stem and head combinations
Implant date

For LFIT V40 cases: Compatible stems include:

Accolade TMZF
Accolade 2
Citation
Meridian
Rejuvenate
Other Stryker stems

Substantial significance. Wrong product identification:

Disqualifies otherwise valid case
Strengthens valid case substantially
Determines applicable MDL/settlement program

Documenting the injury

Strong case requirements:

Symptom documentation:

Onset of hip pain
Progression of symptoms
Functional limitations
Medical evaluations
Specialist consultations

Imaging studies:

X-rays showing implant
MRI showing pseudotumor or ALTR
CT scans
Comparison to baseline

Metal ion testing:

Blood cobalt levels
Blood chromium levels
Trending over time
Reference: >7 ppb concerning

Surgical records (revision):

Operative report from revision
Pathology of tissue
Components removed
Surgical complications
Recovery documentation

Subsequent medical history:

Pain management
Functional recovery
Additional surgeries
Complications

Statute of limitations analysis

Most states have 2-4 year limitations:

Discovery rule typically applies
Limitations begin when patient knew or should have known
Some patients with delayed discovery have viable cases
Some 2014 settlement framework participants may have additional rights

How Stryker hip litigation compares to other medical device mass torts

The litigation has distinctive features:

Compared to Bard hernia mesh MDL 2846: Both involve substantial medical device recalls and $1+ billion settlements. Bard hernia mesh used 510(k) clearance; Stryker hip used PMA process. Both reached comprehensive settlement frameworks.

Compared to Bard PowerPort MDL 3081: Both involve medical device manufacturing defects. PowerPort is active with bellwethers approaching; Stryker hip is substantially resolved with limited new cases.

Compared to Exactech device recall MDL 3044: Both involve orthopedic device recalls with substantial injuries. Exactech faces bankruptcy complications; Stryker had substantial financial capacity for global settlement.

Compared to Allergan Biocell MDL 2921: Both involve medical device litigation. Allergan has substantial PMA preemption issues; Stryker hip didn't face same preemption challenges.

Compared to DePuy ASR hip implant litigation (separate): DePuy ASR was earlier comparable hip implant litigation with substantial settlement. Different defendant but similar product theory.

Compared to Singulair MCL 637: Stryker hip used federal MDL structure; Singulair uses state court (NJ MCL). Different procedural frameworks but similar consolidation approach.

Distinctive Stryker features:

TWO parallel MDLs for different product lines
$1.4 billion global settlement (Rejuvenate/ABG II)
$300,000 minimum award (substantial baseline)
$75 million LFIT V40 settlement
Substantially resolved litigation
Limited new case acceptance
Strong settlement framework for similar future device mass torts
Tritanium Acetabular Shell emerging litigation
Joint federal MDL + state court consolidation (NJ MCL)

Settlement projections for remaining cases

For current and prospective plaintiffs with documented Stryker hip injuries:

Rejuvenate/ABG II cases:

Most eligible cases were resolved in 2014-2018 settlement
Remaining cases may involve:
- Late-emerging complications
- Subsequent revisions
- Discovery rule cases
Settlement framework continues operating
New cases substantially limited

LFIT V40 cases:

2021 settlement framework continues
Remaining cases may receive offers
Individual case evaluation
Range varies substantially with injury severity
Some new cases still accepted

Tritanium Acetabular Shell cases:

Pre-MDL phase
Growing case inventory
Substantial growth potential
Different settlement framework will eventually emerge

Tax implications. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for substantial settlements, particularly when other tax debt issues exist or when reasonable cause penalty defenses apply.

Strategic considerations

For affected patients and prospective plaintiffs:

Identify the specific Stryker product carefully. Critical first step:

Surgical records (operative report)
Implant card if available
Hospital records
Lot numbers
Component identification

Document the injury comprehensively. Strong cases include:

Symptom timeline
Imaging studies (MRI especially)
Metal ion blood testing
Surgical records (especially revision)
Pathology of removed tissue
Subsequent treatment history
Functional impact documentation

Address the statute of limitations carefully. Most cases:

2-4 year limitations period
Discovery rule applicability
Some delayed discovery cases viable
Some 2014 settlement participants may have additional rights

Engage experienced Stryker hip counsel. Substantial procedural complexity:

Settlement program navigation
Individual case evaluation
Medical record analysis
Substantial firm-specific Stryker expertise valuable

Consider future complications. Per Rejuvenate/ABG II settlement:

Future compensation provision
Subsequent complications eligible
Long-term framework

Document subsequent medical treatment. Strong cases include:

All medical care related to implant
Revision surgery documentation
Complication treatment
Ongoing pain management
Functional impact

Address the Tritanium Acetabular Shell separately. Different framework:

Emerging litigation
Pre-MDL phase
Different case evaluation
Substantial growth potential

Plan for the substantial wait. Settlement processing:

Application
Medical review
Independent evaluation
Settlement offer
Acceptance or rejection
Typically 6-18 months total

Coordinate with treating providers. Orthopedic surgeons, pain management specialists, and other treating physicians are important witnesses. Their assessment of causation strengthens cases.

Address related tax planning. Personal injury settlements for physical injuries are tax-free. Coordinate with tax counsel for substantial settlements. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe metallosis cases:

Cardiomyopathy from systemic cobalt
Other serious complications
Wrongful death applicable
Estate has standing
Surviving family members may have separate claims

Document the lifestyle impact. Strong cases show:

Pre-implant functional baseline
Loss of function post-implant
Inability to return to work
Recreational activity loss
Daily life impact

Coordinate medical and legal timelines. Some patients face decision between:

Immediate revision (medical necessity)
Delayed revision (case development)

Medical necessity should dominate, but legal counsel can advise on timing implications.

Consider state court alternatives. Beyond federal MDL:

New Jersey MCL 624 (parallel state court)
Other state court actions
Different procedural framework
May benefit some specific case profiles

Address the medical monitoring component. Even after revision:

Continued cobalt/chromium monitoring
Long-term surveillance for complications
Future revisions possible
Ongoing medical care

Don't accept inadequate settlement offers without thorough evaluation. Many cases:

Substantial injury justifies more than initial offers
Negotiate based on documented damages
Consider litigation if settlement insufficient
Multiple revision cases may justify substantially higher amounts

For affected patients with documented Stryker hip implant injuries, the framework provides substantial compensation through established settlement programs that have resolved the majority of cases. The Rejuvenate/ABG II $1.4 billion settlement with $300,000 minimum awards remains one of the largest minimum settlement provisions in hip replacement litigation history, and the LFIT V40 $75 million settlement provided substantial individual case evaluation framework. Both MDLs technically remain open with some new case acceptance, particularly for the LFIT V40 product line. The emerging Tritanium Acetabular Shell litigation represents the next phase of Stryker hip implant mass tort framework. The work for affected patients is in comprehensive product identification through surgical records, thorough injury documentation including metal ion testing and revision surgery records, engagement with experienced Stryker hip counsel familiar with settlement program navigation, coordination of medical and legal timelines, and careful consideration of statute of limitations issues. For patients with substantial documented injuries meeting eligibility requirements, the established settlement frameworks provide meaningful compensation reflecting the serious nature of metal-on-metal hip implant failure and the substantial medical, surgical, and lifestyle consequences for affected patients.